Skip to main content
Clinical Trials/PACTR202607567738879
PACTR202607567738879Active, not recruitingPhase 3

Microneedling with methotrexate versus intralesional steroid in the treatment of localized vitiligo

Al Azhar university0 sites36 target enrollmentStarted: April 25, 2023Last updated:
Conditions
Interventions

Trial Snapshot

Phase
Phase 3
Status
Active, not recruiting
Enrollment
36

Study Overview

Brief Summary

No summary available.

Study Design

Study Type
Interventional

Eligibility Criteria

Ages
18 Year(s) to 44 Year(s) (—)
Sex
All

Inclusion Criteria

  • Co-operative patient who is willing and able to comply with the treatment protocol and follow-up visits.
  • Participants must have stable vitiligo, meaning that the extent and severity of their vitiligo have not significantly changed in the past 6 months

Exclusion Criteria

  • Patients with keloidal tendency.
  • Patients receiving topical or systemic treatment for vitiligo and phototherapy during the previous 6 months.
  • Patients with active lesions.
  • Participants with a history of hypersensitivity to methotrexate or any of its excipients.
  • Participants with a history of liver disease or liver function abnormalities.
  • Participants with a history of bleeding disorders or receiving anticoagulant therapy.
  • Participants who are pregnant or breastfeeding.
  • Participants with active skin infections or skin conditions that would contraindicate the use of microneedling or intralesional injections.

Arms & Interventions

;Intralesional steroids;Microneedling with methotrexate

Intervention: ;Intralesional steroids;Microneedling with methotrexate

Investigators

Similar Trials